News


All series


All News

A combination of the oral proteasome inhibitor ixazomib (Ninlaro), lenalidomide (Revlimid) and dexamethasone has been approved by the FDA a full 4 months ahead of schedule for patients with multiple myeloma with at least 1 prior surgery.

Patients receiving a combination of MEK inhibitor trametinib and BRAF inhibitor dabrafenib not only greatly improves long-term outcomes, but also lowers some adverse events associated with either standalone agent for patients with BRAF-mutated metastatic melanoma.

Despite the small size of the pigeon brain, our Columba livia counterparts have performed just as well as humans in distinguishing between normal tissue and breast cancer tissue in a study performed by researchers at the University of Iowa and the University of California, Davis.

The FDA has given accelerated approval to the CD38-targeted monoclonal antibody daratumumab as a monotherapy for patients with multiple myeloma following at least 3 prior therapies a full four months ahead of schedule.